2023 was another good year for MVIC. We have had, and are having, a range of customers in various fields of inhaled drug delivery including formulation development, measurement undertakings and nonclinical activities. Furthermore, MVIC member companies are without exception doing well. We are a commercial CRO but many activities are scientific and we have several links to academia. We are excited to move into 2024 – please contact us and share your challenges in inhaled drug delivery. I am sure we can help!
Lars Asking, CEO of MVIC